has the whole industrial chain of R&D, manufacturing, and commercialization. We committed to provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established.
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for 君迈康® (Adalimumab)
Mabwell Included in the List of 2021 New Shanghai Technology Innovation Center